Finally, cemiplimab, a highly potent anti-PD-1 already approved for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), is being evaluated in monotherapy vs. investigator’s choice platinum-doublet chemotherapy in patients with advanced NSCLC and PD-L1 TPS ≥50% (EMPOWER Lung-01 trial [37]). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.